Evaluating the Point prevalence of drug-drug interaction in cardiac patient at tertiary care hospital
International Journal of Drug Delivery Technology · 13.04.2026 · 16 (8s)
DOI: 10.25258/ijddt.16.8s.68 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 13.04.2026. Verfasst von Shailesh H. Kendre und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Cardiovascular disease with comorbidities demands complex drug regimens, increasing the risk of drug-drug interactions (DDIs). DDIs can compromise therapeutic outcomes through altered metabolism or synergistic effects, especially in polypharmacy settings. Indian cardiac inpatients face rising DDI risks amid limited awareness and variable prescribing practices. This study evaluates the prevalence, severity, and potential clinical Impact of DDIs in a tertiarycare cardiology unit A prospective observational cross-sectional study was conducted over six months at Deenanath Mangeshkar Hospital, Pune. 375 cardiovascular inpatients aged >18 years were enrolled using convenient sampling at discharge. Discharge prescriptions were screened for drug-drug interactions (DDIs) using the Micromedex database. Primary outcome was DDI prevalence; secondary outcomes included severity, mechanism, and clinical consequences. Data were collected via structured Case Report Forms and analyzed using descriptive statistics in Excel. Stratification by age, sex, and medication count explored subgroup patterns; missing data were excluded. Bias was minimized through standardized tools and independent verification, though sampling may limit generalizability Among 375 hospitalized cardiac patients, 61.6% experienced at least one drug-drug interaction (DDI), with a total of 621 drug-drug interaction identified. Moderate (51.8%) and severe (47.5%) interactions dominated, mostly pharmacokinetic in nature (56.0%), primarily due to altered metabolism. Frequent drug pairs included thromboxane inhibitors with p2y12 blockers and factor xa inhibitors. Micromedex data suggested potential risks like hypoglycemia (31.1%) and bleeding (17.4%).
Zitieren
APA
Kendre, S. H., Jadhav, S. P., Ghundre, S. K., Arbane, Y. M., Mishra, P. R., & Harimkar, S. R. (2026). Evaluating the Point prevalence of drug-drug interaction in cardiac patient at tertiary care hospital. International Journal of Drug Delivery Technology, 16(8s). https://doi.org/10.25258/ijddt.16.8s.68
Vancouver
Kendre SH, Jadhav SP, Ghundre SK, Arbane YM, Mishra PR, Harimkar SR. Evaluating the Point prevalence of drug-drug interaction in cardiac patient at tertiary care hospital. International Journal of Drug Delivery Technology. 2026;16(8s). doi:10.25258/ijddt.16.8s.68
BibTeX
@article{Kendre2026,
author = {Kendre, Shailesh H. and Jadhav, Sayali P. and Ghundre, Sakshi K. and Arbane, Yashraj M. and Mishra, Prashant R. and Harimkar, Sanket R.},
title = {Evaluating the Point prevalence of drug-drug interaction in cardiac patient at tertiary care hospital},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {8s},
doi = {10.25258/ijddt.16.8s.68}
}
EUVIMED